Abstract
The paper focuses on the β-emitting radionuclides which might be useful for peptide receptor radionuclide therapy, PRRT. For the effective design of the radiopharmaceutical, the choice of radionuclide will depend on the purpose for which the radioligand is being used and on the physicochemical properties of the radionuclide. The important factor is also the availability and the cost of production. The physical characteristics of several radionuclides which are currently used or can be considered as potential candidates for PRRT is provided, followed by short description of production methods and chemical aspects of their use in preparation of peptide-based radiopharmaceuticals. Somatostatin analogues labeled with radionuclides have been a successful example of PRRT. For treatment of patients with inoperable or metastasized neuroendocrine tumors, somatostatin analogues labeled with the radioisotopes 111In, 90Y and 177Lu have been used so far. Labeling with 111In, mainly an Auger electron emitter, resulted in no reduction of tumor size while somatostatin analogues labeled with 90Y and 177Lu gave overall positive response and improved the patients’ quality of life. These promising results together with the increasing availability of other β-emitting radionuclides are a good basis for further studies.
Keywords: Beta-emitting radionuclides, radiolabeling, radionuclide therapy, PRRT
Current Topics in Medicinal Chemistry
Title:Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy
Volume: 12 Issue: 23
Author(s): J. L. Parus and R. Mikolajczak
Affiliation:
Keywords: Beta-emitting radionuclides, radiolabeling, radionuclide therapy, PRRT
Abstract: The paper focuses on the β-emitting radionuclides which might be useful for peptide receptor radionuclide therapy, PRRT. For the effective design of the radiopharmaceutical, the choice of radionuclide will depend on the purpose for which the radioligand is being used and on the physicochemical properties of the radionuclide. The important factor is also the availability and the cost of production. The physical characteristics of several radionuclides which are currently used or can be considered as potential candidates for PRRT is provided, followed by short description of production methods and chemical aspects of their use in preparation of peptide-based radiopharmaceuticals. Somatostatin analogues labeled with radionuclides have been a successful example of PRRT. For treatment of patients with inoperable or metastasized neuroendocrine tumors, somatostatin analogues labeled with the radioisotopes 111In, 90Y and 177Lu have been used so far. Labeling with 111In, mainly an Auger electron emitter, resulted in no reduction of tumor size while somatostatin analogues labeled with 90Y and 177Lu gave overall positive response and improved the patients’ quality of life. These promising results together with the increasing availability of other β-emitting radionuclides are a good basis for further studies.
Export Options
About this article
Cite this article as:
L. Parus J. and Mikolajczak R., Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy, Current Topics in Medicinal Chemistry 2012; 12 (23) . https://dx.doi.org/10.2174/1568026611212230006
DOI https://dx.doi.org/10.2174/1568026611212230006 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways
Current Pharmaceutical Design Immunotherapy for Myeloproliferative Neoplasms (MPN)
Current Cancer Drug Targets A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Toxin-Labeled Monoclonal Antibodies
Current Pharmaceutical Biotechnology Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Exploiting APC Function as a Novel Cancer Therapy
Current Drug Targets Aldose Reductase: A Novel Target for Cardioprotective Interventions
Current Drug Targets Chondroitin Sulphate for the Treatment of Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Modelling the Impact of Antiretroviral Therapy on the Epidemic of HIV
Current HIV Research Effects of Natural Compounds on Xenopus Embryogenesis: A Potential Read Out for Functional Drug Discovery Targeting Wnt/β-catenin Signaling
Current Topics in Medicinal Chemistry Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry PPARγ Pro12Ala Polymorphism in HIV-1-Infected Patients with HAARTRelated Lipodystrophy
Current HIV Research Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology Notch Signaling in Leukemias and Lymphomas
Current Molecular Medicine Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Current Pharmaceutical Design Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance
Current Topics in Medicinal Chemistry